Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Hong Kong Buybacks: AIA, JD Health, Skyworth

Hong Kong Buybacks: AIA, Smoore, JD Health

Hong Kong Buybacks: Tencent, AIA, and Xiaomi

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on May 6th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Aia Group (1299 HK), Jd Health (6618 HK), Skyworth (751 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Aia Group (1299 HK), Tencent (700 HK), Xiaomi (1810 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on May 6th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Aia Group (1299 HK), Jd Health (6618 HK), Skyworth (751 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Aia Group (1299 HK), Tencent (700 HK), Xiaomi (1810 HK).
